ClinicalTrials.gg

Program

entecavir

Also written as “Entecavir”, “Entecavir (ETV)” and “Entecavir + Tenofovir”.

Its studies are mostly in Hepatitis B, Chronic · Hepatitis B, led by 6 companies.

Furthest: phase 4, since Aug 29, 200632 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb240 open or runningphase 4since Aug 29, 2006May 4, 2002none ahead
Hoffmann-La Roche40 open or runningphase 4since Jan 30, 2008Jan 30, 2008none ahead
Ascentage Pharma Group International11 open or runningphase 2since Sep 24, 2020Sep 24, 2020none ahead
aucta-pharmaceuticals-inc10 open or runningphase 1since Jul 27, 2017Jul 27, 2017none ahead
Hanmi Pharmaceutical10 open or runningphase 4since Jul 26, 2015Jul 26, 2015none ahead
Sino Biopharmaceutical10 open or runningno phasesince Jan 22, 2019Jan 22, 2019none ahead

Also a collaborator on its studies: icon-clinical-research and cpr-pharma-services-pty-ltd-australia.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 16 studies since May 4, 2002.

  1. Sep 8, 2009Phase 3 study in Hepatitis B, ChronicBristol-Myers Squibb · NCT00975091 · 600 enrolled
  2. Sep 29, 2009Phase 4 study in Hepatitis B, ChronicBristol-Myers Squibb · NCT00986778
  3. Nov 24, 20092 phase 2 studies in Hepatitis B, ChronicBristol-Myers Squibb · NCT01020565, NCT01022801
  4. Dec 17, 20092 phase 2 studies in Hepatitis B, ChronicBristol-Myers Squibb · NCT01037166, NCT01037062
  5. Feb 3, 2010Phase 3 study in Hepatitis B, ChronicBristol-Myers Squibb · NCT01063036 · 144 enrolled · France, Germany, Italy and more
  6. Mar 2, 2010Phase 3 study in Hepatitis B, ChronicBristol-Myers Squibb · NCT01079806 · 180 enrolled · United States, Argentina, Belgium and more
  7. Aug 10, 2010Phase 4 study in Hepatitis B, ChronicHoffmann-La Roche · NCT01179594
  8. Sep 16, 2011Phase 2 study in Hepatitis BBristol-Myers Squibb · NCT01438424 · 1,053 enrolled
  9. Oct 2, 2014Phase 3 study in Pediatric Immuno-Tolerant Chronic Hepatitis BHoffmann-La Roche · NCT02263079 · 62 enrolled · United States, Australia, Belgium and more
  10. Jul 26, 2015Hanmi Pharmaceutical's first study: phase 4 study in Hepatitis B, ChronicNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT02523547 · 134 enrolled · Korea, Republic of
  11. Mar 14, 2017Phase 1 study in Hepatitis BBristol-Myers Squibb · NCT03083821 · 6 enrolled · Japan
  12. Jul 27, 2017aucta-pharmaceuticals-inc's first study: phase 1 study in HBVNew to aucta-pharmaceuticals-incaucta-pharmaceuticals-inc · NCT03239353 · 40 enrolled · Australia
  13. Jan 22, 2019Sino Biopharmaceutical's first study: no phase study in Hepatitis B, ChronicNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT03847246 · 26 enrolled · China
  14. Sep 24, 2020Ascentage Pharma Group International's first study: phase 2 study in Hepatitis BNew to Ascentage Pharma Group InternationalAscentage Pharma Group International · NCT04568265 · 122 planned · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“DNA polymerase/reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

All 32 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT04568265Hepatitis B · China2RecruitingAscentage Pharma Group InternationalOct 31, 2022122
NCT03847246Hepatitis B, Chronic · China–CompletedSino BiopharmaceuticalDec 28, 201826
NCT03239353HBV · Australia1Completedaucta-pharmaceuticals-incMay 29, 201840
NCT03083821Hepatitis B · Japan1CompletedBristol-Myers SquibbDec 19, 20176
NCT02523547Hepatitis B, Chronic · Korea, Republic of4UNKNOWNHanmi PharmaceuticalFeb 2017134
NCT02263079Pediatric Immuno-Tolerant Chronic Hepatitis B · United States, Australia, Belgium and more3CompletedHoffmann-La RocheJan 29, 202062
NCT01438424Hepatitis B2CompletedBristol-Myers SquibbDec 20091,053
NCT01179594Hepatitis B, Chronic4WithdrawnHoffmann-La RocheNov 20140
NCT01079806Hepatitis B, Chronic · United States, Argentina, Belgium and more3CompletedBristol-Myers SquibbMar 31, 2013180
NCT01063036Hepatitis B, Chronic · France, Germany, Italy and more3CompletedBristol-Myers SquibbNov 2012144
NCT01037166Hepatitis B, Chronic · Japan2CompletedBristol-Myers SquibbFeb 200584
NCT01037062Hepatitis B, Chronic · Japan2CompletedBristol-Myers SquibbDec 2006282
NCT01022801Hepatitis B, Chronic2CompletedBristol-Myers SquibbMar 2005120
NCT01020565Hepatitis B, Chronic2CompletedBristol-Myers SquibbFeb 200560
NCT00986778Hepatitis B, Chronic4WithdrawnBristol-Myers SquibbDec 20120
NCT00975091Hepatitis B, Chronic3CompletedBristol-Myers SquibbAug 2007600
NCT00922207Hepatitis B, Chronic · Taiwan4CompletedHoffmann-La RocheSep 29, 2014280
NCT00718887Hepatitis B, Chronic · China4CompletedBristol-Myers SquibbDec 2009228
NCT00614471Hepatitis B, Chronic · China, Hong Kong4CompletedHoffmann-La RocheOct 2009219
NCT00605384Hepatitis B, Chronic · United States, Belgium, Germany and more3TerminatedBristol-Myers SquibbFeb 20094
NCT00423891Hepatitis B, Chronic · United States, Argentina, Belgium and more2CompletedBristol-Myers SquibbAug 31, 201364
NCT00410202Hepatitis B, Chronic · United States, Australia, Brazil and more3CompletedBristol-Myers SquibbJan 2011629
NCT00410072Hepatitis B, Chronic · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbOct 2010669
NCT00395018Hepatitis B, Chronic · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbMar 2011109
NCT00393484Hepatitis B, Chronic · Korea, Republic of4CompletedBristol-Myers SquibbJan 2009122
NCT00371150Hepatitis B · United States, Brazil, Mexico and more4CompletedBristol-Myers SquibbMar 2011131
NCT00096785Hepatitis B · United States, Canada, Hong Kong and more3CompletedBristol-Myers SquibbJan 200669
NCT00065507Hepatitis B · United States, Brazil, Canada and more3CompletedBristol-Myers SquibbOct 2008195
NCT00051038Hepatitis B · United States3CompletedBristol-Myers SquibbOct 2005
NCT00036608Hepatitis B, Chronic · United States3CompletedBristol-Myers SquibbFeb 2005
NCT00035789Hepatitis B, Chronic · United States3CompletedBristol-Myers SquibbMay 2005
NCT00035633Hepatitis B, Chronic · United States3CompletedBristol-Myers SquibbFeb 2005

How it is read

Names in the registry

  • “Entecavir”, 28 entries
  • “entecavir”, 4 entries
  • “Entecavir (ETV)”, 2 entries
  • “Entecavir + Tenofovir”, 2 entries
  • “P1101 + Nivolumab + Entecavir”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.